Hormonal
Tirzepatide (15 mg) produces a greater improvement in insulin sensitivity per unit of weight loss compared to semaglutide (1 mg) in patients with type 2 diabetes, suggesting mechanisms beyond simple adiposity reduction.
If you are treating type 2 diabetes with GLP-1 based therapies, tirzepatide (15 mg) appears to offer superior improvements in how your body uses insulin for every pound lost, compared to semaglutide (1 mg). This suggests tirzepatide works through additional hormonal pathways (GIP/GLP-1) beyond just reducing fat mass. For patients prioritizing metabolic health improvements alongside weight loss, this distinction may be clinically relevant.
Tirzepatide was associated with a greater improvement than semaglutide in insulin sensitivity assessed using hyperinsulinemic euglycemic clamps (p < 0.001)... In regression analysis, tirzepatide was associated with greater improvement in insulin sensitivity per unit weight loss than semaglutide.
Why this rating
The study uses the gold-standard hyperinsulinemic euglycemic clamp and mixed-meal tolerance testing, but it is a post hoc exploratory analysis of a single trial with a specific demographic (older males).
Source
Greater improvement in insulin sensitivity per unit weight loss associated with tirzepatide versus semaglutide: An exploratory analysis
Kieren J. Mather et al. · Diabetes Obesity and Metabolism · 2025
DOI 10.1111/dom.16159
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →